Since four RUNX1 binding sites were identified in the KLF4 promoter in a human leukemia cell model [52] and KLF4 has been determined as an AR gene target in breast cancer cell lines [53], more experiments are needed to define the principal source of KLF4 gene expression activation. Here, RUNX1 is linked to breast carcinoma.